HLX03

DRUG2 trials

Sponsors

Shanghai Henlius Biotech

Conditions

Immune System DisorderPlaque Psoriasis

Phase 1

Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

CompletedNCT03357939

Shanghai Henlius BiotechImmune System Disorder

Start: 2017-01-12End: 2018-09-15Updated: 2022-05-09

Phase 3

Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis

CompletedNCT03316781

Shanghai Henlius BiotechPlaque Psoriasis

Start: 2017-10-27End: 2019-04-22Updated: 2025-08-13

Related Papers

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy2021-11-2313 citations